Gilead Stock News

Gilead unveiled mixed results for its drug Trodelvy in women with breast cancer on Monday — but GILD stock recovered from a premarket dive.

Gilead Sciences (GILD) Trodelvy (sacituzumab) met its primary endpoint in a late-stage trial in patients with HR+/HER2- metastatic breast cancer.

Smart Beta ETF report for IBB

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB ) retreated in four out of five sessions of the week. Clinical trial updates and FDA-related news moved stocks, while earnings news flow tapered off. NuCana plc. (NASDAQ: NCNA ) was among the worst decliners of the week, with the stock reacting to the stalling of the company''s Phase 3 biliary tract cancer study. SAB Biotherapeutics, Inc. (NASDAQ: SABS ) shares also came under pressure after the National Institutes of Health pulled the plug on a Phase study of the company''s SAB-185 in COVID-19 patients. Celayad Oncology SA (NASDAQ: CYAD ) shares plunged after the company said it is pulling the plug on an early-stage biliary tract cancer study. FDA decisions scheduled for the week were mixed, with Amryt Pharma plc (NASDAQ: AMYT ) and Gilead Sciences, Inc. (NASDAQ: GILD ) failing to get their investigational drugs across the finish line.

A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates.

Looking for stocks whose earnings returns are more than double the monthly spot rate of 20-year high-quality market corporate bonds could provide more opportunities to discover high-return investments

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd. , Novartis AG, Gilead Sciences Inc. , Bayer AG and Takeda Pharmaceticals. The global oncology drugs market is expected to grow from $199. Major companies in the oncology drugs market include F. Hoffmann-La Roche Ltd. , Novartis AG, Gilead Sciences Inc. , Bayer AG and Takeda Pharmaceticals. The global oncology drugs market is expected to grow from $199.

Major companies in the anti-infective drugs market include Gilead Sciences, GlaxosmithKline, Merck & Co. , Johnson & Johnson, Pfizer Inc. , AbbVie, Bayer AG, Mylan N. V. , Shionogi and F. Hoffmann-La Roche Ltd. Major companies in the anti-infective drugs market include Gilead Sciences, GlaxosmithKline, Merck & Co. , Johnson & Johnson, Pfizer Inc. , AbbVie, Bayer AG, Mylan N. V. , Shionogi and F. Hoffmann-La Roche Ltd.

We have always championed dividend stocks at 24/7 Wall St., especially those with higher payouts and growth rates.

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead (GILD) reported earnings 30 days ago. What's next for the stock?

Gilead Sciences ( GILD , Financial) had a particularly strong 2021 with the full-year revenue being 11% higher than the midpoint of their initial guidance released in February 2021. The impact of Covi